Indication: Oral Mucositis

A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy

Pts receiving chemo for Head & Neck cancer

Sub-indication: Therapy trial to reduce severe oral mucositis

Line of Therapy: Newly diagnosed

Drug Study

Principal Investigator: Aaron Spalding, M.D.
Norton Cancer Institute

Sponsor: Oragenics Inc.

Learn more at ClinicalTrials.gov

Email for more information: Head&Neck-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.